AMRX
Amneal Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
21.35
close · 2026-10-29
value
29
cheaper than peers29
quality
64
stronger fundamentals64
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.89× | 64 |
| EV to EBITDA | 12.62× | 54 |
| forward P/E | 17.74× | 30 |
| price to book | 207.28× | 1 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 613.0% | 99 |
| operating margin | 18.4% | 74 |
| revenue growth | 9.9% | 61 |
| debt to equity | 2386.5% | 1 |
4 of 4 measures available
Facts
| market cap | $7B |
| free cash flow | -$115.7M |
| employees | 8,700 |
| first trade | 2018-05-07 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.22 | -0.38 | -0.48 | -0.86 |
| free cash flow | $225.6M | $220.1M | $276.4M | -$25.5M |
| net income | $72.1M | -$116.9M | -$84.0M | -$130.0M |
| revenue | $3.02B | $2.79B | $2.39B | $2.21B |
| unusual items | -$2.8M | -$156.6M | -$35.8M | -$296.8M |